{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:47:10Z","timestamp":1790754430740,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jprot.2013.10.031","type":"journal-article","created":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T17:53:36Z","timestamp":1383242016000},"page":"44-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors"],"prefix":"10.1016","volume":"96","author":[{"given":"Xin","family":"Ku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-6565","authenticated-orcid":false,"given":"Stephanie","family":"Heinzlmeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-4671","authenticated-orcid":false,"given":"Xiaofeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-4029","authenticated-orcid":false,"given":"Guillaume","family":"M\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jprot.2013.10.031_bb0005","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jprot.2013.10.031_bb0010","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1074\/mcp.R800006-MCP200","article-title":"Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care","volume":"7","author":"Kruse","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.jprot.2013.10.031_bb0015","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jprot.2013.10.031_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nchembio.1113","article-title":"A public\u2013private partnership to unlock the untargeted kinome","volume":"9","author":"Knapp","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jprot.2013.10.031_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jprot.2013.10.031_bb0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.chembiol.2012.01.002","article-title":"Mass spectrometry-based proteomics in preclinical drug discovery","volume":"19","author":"Schirle","year":"2012","journal-title":"Chem Biol"},{"key":"10.1016\/j.jprot.2013.10.031_bb0035","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ymeth.2012.05.008","article-title":"Mass spectrometry approaches to monitor protein\u2013drug interactions","volume":"57","author":"Zinn","year":"2012","journal-title":"Methods"},{"key":"10.1016\/j.jprot.2013.10.031_bb0040","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.bmc.2011.11.003","article-title":"Chemoproteomic approaches to drug target identification and drug profiling","volume":"20","author":"Bantscheff","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jprot.2013.10.031_bb0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nbt.1658","article-title":"Proteomics: a pragmatic perspective","volume":"28","author":"Mallick","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jprot.2013.10.031_bb0050","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00216-007-1486-6","article-title":"Quantitative mass spectrometry in proteomics: a critical review","volume":"389","author":"Bantscheff","year":"2007","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jprot.2013.10.031_bb0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00216-012-6261-7","article-title":"Quantitative mass spectrometry in proteomics","volume":"404","author":"Bantscheff","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jprot.2013.10.031_bb0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-61779-337-0_11","article-title":"Kinase inhibitor profiling using chemoproteomics","volume":"795","author":"Schirle","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jprot.2013.10.031_bb0065","doi-asserted-by":"crossref","first-page":"15434","DOI":"10.1073\/pnas.2535024100","article-title":"An efficient proteomics method to identify the cellular targets of protein kinase inhibitors","volume":"100","author":"Godl","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jprot.2013.10.031_bb0070","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1124\/mol.62.6.1364","article-title":"Discovery of novel targets of quinoline drugs in the human purine binding proteome","volume":"62","author":"Graves","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jprot.2013.10.031_bb0075","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1021\/bi062142x","article-title":"Functional interrogation of the kinome using nucleotide acyl phosphates","volume":"46","author":"Patricelli","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.jprot.2013.10.031_bb0080","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jprot.2013.10.031_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.332","article-title":"A chemical and phosphoproteomic characterization of dasatinib action in lung cancer","volume":"6","author":"Li","year":"2010","journal-title":"Nat Chem Biol"},{"issue":"M111","key":"10.1016\/j.jprot.2013.10.031_bb0090","first-page":"011635","article-title":"Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer","volume":"10","author":"Wu","year":"2011","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"10.1016\/j.jprot.2013.10.031_bb0095","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1021\/pr301073j","article-title":"Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity","volume":"12","author":"Lemeer","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jprot.2013.10.031_bb0100","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nmeth.1373","article-title":"Proteomics strategy for quantitative protein interaction profiling in cell extracts","volume":"6","author":"Sharma","year":"2009","journal-title":"Nat Methods"},{"issue":"8","key":"10.1016\/j.jprot.2013.10.031_bb0105","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1021\/pr400455j","article-title":"Characterization of a chemical affinity probe targeting AKT kinases","volume":"12","author":"Pachl","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jprot.2013.10.031_bb0110","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1021\/pr3008495","article-title":"Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling","volume":"12","author":"Zhang","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jprot.2013.10.031_bb0115","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jprot.2013.10.031_bb0120","first-page":"850","article-title":"Mechanisms of FGFR-mediated carcinogenesis","volume":"2012","author":"Ahmad","year":"1823","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jprot.2013.10.031_bb0125","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1021\/pr400455j","article-title":"Characterization of a chemical affinity probe targeting AKT kinases","volume":"12","author":"Pachl","year":"2013","journal-title":"J Proteome Res"},{"issue":"M111","key":"10.1016\/j.jprot.2013.10.031_bb0130","first-page":"016675","article-title":"Systematic identification of the HSP90 candidate regulated proteome","volume":"11","author":"Wu","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.jprot.2013.10.031_bb0135","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1074\/mcp.T500030-MCP200","article-title":"Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap","volume":"4","author":"Olsen","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.jprot.2013.10.031_bb0140","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1093\/emboj\/17.20.5896","article-title":"Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain","volume":"17","author":"Mohammadi","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.jprot.2013.10.031_bb0145","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-10-2727","article-title":"FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo","volume":"17","author":"Sharpe","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jprot.2013.10.031_bb0150","doi-asserted-by":"crossref","first-page":"8645","DOI":"10.1158\/0008-5472.CAN-09-1576","article-title":"The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo","volume":"69","author":"Pardo","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jprot.2013.10.031_bb0155","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/jm000271k","article-title":"Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases","volume":"43","author":"Barvian","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.jprot.2013.10.031_bb0160","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jprot.2013.10.031_bb0165","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1158\/0008-5472.CAN-05-0574","article-title":"Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling","volume":"65","author":"Godl","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jprot.2013.10.031_bb0170","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1021\/jm9904295","article-title":"Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases","volume":"42","author":"Sun","year":"1999","journal-title":"J Med Chem"},{"issue":"Suppl. 4","key":"10.1016\/j.jprot.2013.10.031_bb0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1179\/joc.2004.16.Supplement-1.59","article-title":"Vascular endothelial growth factor (VEGF) inhibition by small molecules","volume":"16","author":"Ahmed","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.jprot.2013.10.031_bb0180","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1210\/jc.2005-2845","article-title":"An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET\/papillary thyroid cancer kinases","volume":"91","author":"Kim","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jprot.2013.10.031_bb0185","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature08995","article-title":"Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis","volume":"465","author":"Sawamiphak","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jprot.2013.10.031_bb0190","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature09002","article-title":"Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis","volume":"465","author":"Wang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jprot.2013.10.031_bb0195","doi-asserted-by":"crossref","first-page":"e23971","DOI":"10.1371\/journal.pone.0023971","article-title":"Functional dissection of the TBK1 molecular network","volume":"6","author":"Goncalves","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2013.10.031_bb0200","doi-asserted-by":"crossref","first-page":"37029","DOI":"10.1074\/jbc.M205069200","article-title":"Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases","volume":"277","author":"Chariot","year":"2002","journal-title":"J Biol Chem"}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391913005460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391913005460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T17:16:13Z","timestamp":1564593373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391913005460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":40,"alternative-id":["S1874391913005460"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2013.10.031","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2013.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}